Overall survival as a primary end point in multiple myeloma trials
Nat Rev Clin Oncol
.
2022 Sep;19(9):565-566.
doi: 10.1038/s41571-022-00665-7.
Authors
Edward R Scheffer Cliff
1
2
,
Ghulam Rehman Mohyuddin
3
Affiliations
1
Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ecliff@hsph.harvard.edu.
2
Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. ecliff@hsph.harvard.edu.
3
Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
PMID:
35821523
DOI:
10.1038/s41571-022-00665-7
No abstract available
MeSH terms
Clinical Trials as Topic*
Humans
Multiple Myeloma* / drug therapy
Multiple Myeloma* / mortality
Survival Analysis